RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: APT 2
Target: Mixed lineage leukemia protein 1 (MLL1)
Type of nucleic acid: ssRNA
Sequence: 5′GGCUCGAGGACGUAACAGAGGGAGGCGAGUGGGUGGAAGCUUACGGUACCUAGC3′
Sequence length: 54
GC content: 0.6111111111111112
Affinity: Not reported
Pool type: 5′-CGACTCACTATAGGCTCGAGG-N25-GGAAGCTTACGGTACCTAGC-3′
Pool random region: 25
Binding buffer/conditions: NETN buffer media (20 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, and 0.5% NP-40)
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " We suggest that MLL1-specific aptamers could be further developed for useful applications in various areas, including as therapeutic or diagnostic agents in the biomedical field. APT1 and APT2 are prominent candidates for development of diagnosis or therapy in MLL1-related diseases. First, by developing these aptamers as chemical probes, the function and biological properties can be examined. Second, these aptamers can be tested whether these are used as a therapy related to aberrant regulation of methylase activity of MLL1. In the future, the study of these aptamers will provide deeper insights and more therapeutic potential."
Reference (2019, Biomol Ther (Seoul) ): Ul-Haq, A., Jin, M. L., Jeong, K. W., Kim, H. M., & Chun, K. H. (2019). Isolation of MLL1 Inhibitory RNA Aptamers. Biomolecules & therapeutics, 27(2), 201–209. https://doi.org/10.4062/biomolther.2018.157
Aptamer: S30
Target: CD33 antigen on leukemia cells
Type of nucleic acid: ssDNA
Sequence: 5'TACCAGTGCGATGCTCAGCACGCTTATAGGGGCTGGACAAAATTCTACCCAGCCTTTTCTGACGCATTCGGTTGAC3'
Sequence length: 76
GC content: 0.5131578947368421
Affinity: Kd: 43 nM
Pool type: 5'-TACCAGTGCGATGCTCAG-N40-CTGACGCATTCGGTTGAC-3'
Pool random region: 40
Binding buffer/conditions: 20 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 1 mM CaCl2
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " The optimized aptamer S30-T1 (i.e., core region of S30) was conjugated with doxorubicin (Dox) to synthesize S30-T1-Dox conjugates, which could specifically inhibit CD33 positive acute myeloid leukemia HL-60 cell proliferation by arresting the cell cycle at the G2 phase. Thus, our modified approach can rapidly screen reliable, stable and high binding affinity aptamers for precise cancer treatment."
Reference (2019, Biomater Sci ): Yang, C., , Wang, Y., , Ge, M. H., , Fu, Y. J., , Hao, R., , Islam, K., , Huang, P., , Chen, F., , Sun, J., , Hong, F., , & Naranmandura, H., (2019). Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach. Biomaterials science, 7(3), 938–950. https://doi.org/10.1039/c8bm01393d
Aptamer: D10
Target: Dickkopf-1(DKK1)
Type of nucleic acid: ssDNA
Sequence: 5'TAGGGAAGAGAAGGACATATGATTAGGCCGTAAACGGGGCTAGGCGGGGATCATTGACTAGTACATGACCACTTGA3'
Sequence length: 76
GC content: 0.4868421052631579
Affinity: Kd: 24.86 nM
Pool type: 5′-TAGGGAAGAGAAGGACATATGAT-N30-TTGACTAGTACATGACCACTTGA-3'
Pool random region: 30
Binding buffer/conditions: Phosphate buffered saline with 5 mM MgCl2, 5 mM imidazole, 1% BSA, 1 μg/ml tRNA, 0.02%(v/v) tween-20, pH 7.4
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " In this work, we obtained fast-off and slow-off aptamer recognizing dickkopf-1(DKK1), a promising biomarker for detection of early-stage hepatocellular carcinoma (HCC), with high affinity in a single SELEX procedure. novel DKK1 aptamer could replace capture antibody for potential early HCC diagnosis."
Additional information: Other sequences exist, this is best
Reference (2019, Talanta ): Zhou, Y., Li, W., Tseng, Y., Zhang, J., & Liu, J. (2019). Developing slow-off dickkopf-1 aptamers for early-diagnosis of hepatocellular carcinoma. Talanta, 194, 422–429. https://doi.org/10.1016/j.talanta.2018.10.014
Aptamer: TD10
Target: Dickkopf-1(DKK1)
Type of nucleic acid: ssDNA
Sequence: 5'CATATGATTAGGCTGTAACGGGGCTAGGCGGGGATCATT3'
Sequence length: 39
GC content: 0.5128205128205128
Affinity: Not reported
Pool type: 5′-TAGGGAAGAGAAGGACATATGAT-N30-TTGACTAGTACATGACCACTTGA-3'
Pool random region: 30
Binding buffer/conditions: Phosphate buffered saline with 5 mM MgCl2, 5 mM imidazole, 1% BSA, 1 μg/ml tRNA, 0.02%(v/v) tween-20, pH 7.5
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: D10 truncated from 76nt to 39nt
Application as quoted in the referenced paper: Diagnostic: " In this work, we obtained fast-off and slow-off aptamer recognizing dickkopf-1(DKK1), a promising biomarker for detection of early-stage hepatocellular carcinoma (HCC), with high affinity in a single SELEX procedure. novel DKK1 aptamer could replace capture antibody for potential early HCC diagnosis."
Reference (2019, Talanta ): Zhou, Y., Li, W., Tseng, Y., Zhang, J., & Liu, J. (2019). Developing slow-off dickkopf-1 aptamers for early-diagnosis of hepatocellular carcinoma. Talanta, 194, 422–429. https://doi.org/10.1016/j.talanta.2018.10.014
Aptamer: C-9S
Target: Cervical cancer cells Ca Ski, Human
Type of nucleic acid: ssDNA
Sequence: 5'TTATTCAATTATCGTCCGCTTTAGTGTAATGGTCCGTCCCGCAGTGAATAA3'
Sequence length: 51
GC content: 0.4117647058823529
Affinity: Kd: 19.3 ± 2.9 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N40-AGATAGTAAGTGCAATCT-3′
Pool random region: 40
Binding buffer/conditions: 0.1 mg/mL yeast tRNA, 0.1 mg/mL Salmon sperm DNA, and 1 mg/mL BSA in 25 mM glucose, 0.9 mM CaCl2, and 5 mM MgCl2 in Dulbecco's PBS without calcium and magnesium
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Truncated
Application as quoted in the referenced paper: Diagnostic: " Therefore, on the basis of its excellent targeting properties and inherent functional versatility of aptamer, C-9S holds great potential to become a molecular probe for early detection, in vivo imaging, and targeted therapy for cervical cancer. The results demonstrate the applicability of C-9S at physiological temperature and provide an important foundation for the future study of aptamer-based assays, biomarker discovery, and targeted therapy."
Reference (2019, J Mol Evol ): Wang, J., Gao, T., Luo, Y., Wang, Z., Zhang, Y., Zhang, Y., Zhang, Y., & Pei, R. (2019). In Vitro Selection of a DNA Aptamer by Cell-SELEX as a Molecular Probe for Cervical Cancer Recognition and Imaging. Journal of molecular evolution, 87(2-3), 72–82. https://doi.org/10.1007/s00239-019-9886-8
Aptamer: TNA1
Target: Trachinotus ovatus nervous necrosis virus (GTONNV)
Type of nucleic acid: ssDNA
Sequence: 5'GTCTGAAGTAGACGCAGGAGGCTCGGGGCTCGATATTGTAAAGGGAGTGTGTTTAGGAGGACGTGGTTGGAGTCACACCTGAGTAAGCGT3'
Sequence length: 90
GC content: 0.5333333333333333
Affinity: Kd: 27.47 nM
Pool type: 5′-GTCTGAAGTAGACGCAGGAG-N50-AGTCACACCTGAGTAAGCGT-3′
Pool random region: 50
Binding buffer/conditions: 5 g/L glucose, 1.0 g/L bovine serum albumin, 10 % FBS, 0.1 mg/mL yeast tRNA, 5 mM MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " These aptamers recognized GTONNV-infected cells with high specificity and affinity. The results also showed that these aptamers could inhibit GTONNV infection in vitro and in vivo. Moreover, the selected aptamers could be actively internalized into target cells, indicating their potential in targeted therapy and in the study of GTONNV pathogenesis."
Reference (2019, J Gen Virol ): Yu, Q., Liu, M., Wei, S., Wu, S., Xiao, H., Qin, X., Su, H., & Li, P. (2019). Characterization of ssDNA aptamers specifically directed against Trachinotus ovatus NNV (GTONNV)-infected cells with antiviral activities. The Journal of general virology, 100(3), 380–391. https://doi.org/10.1099/jgv.0.001226
Aptamer: TNA4
Target: Trachinotus ovatus nervous necrosis virus (GTONNV)
Type of nucleic acid: ssDNA
Sequence: 5'GTCTGAAGTAGACGCAGGAGCCTTTCGTGTTTCATTAGTGTGTTTCCATTGGGCGGCTCGGGGCAAAAGGAGTCACACCTGAGTAAGCGT3'
Sequence length: 90
GC content: 0.5222222222222223
Affinity: Kd: 44.09 nM
Pool type: 5′-GTCTGAAGTAGACGCAGGAG-N50-AGTCACACCTGAGTAAGCGT-3′
Pool random region: 50
Binding buffer/conditions: 5 g/L glucose, 1.0 g/L bovine serum albumin, 10 % FBS, 0.1 mg/mL yeast tRNA, 5 mM MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " These aptamers recognized GTONNV-infected cells with high specificity and affinity. The results also showed that these aptamers could inhibit GTONNV infection in vitro and in vivo. Moreover, the selected aptamers could be actively internalized into target cells, indicating their potential in targeted therapy and in the study of GTONNV pathogenesis."
Reference (2019, J Gen Virol ): Yu, Q., Liu, M., Wei, S., Wu, S., Xiao, H., Qin, X., Su, H., & Li, P. (2019). Characterization of ssDNA aptamers specifically directed against Trachinotus ovatus NNV (GTONNV)-infected cells with antiviral activities. The Journal of general virology, 100(3), 380–391. https://doi.org/10.1099/jgv.0.001226
Aptamer: TNA19
Target: Trachinotus ovatus nervous necrosis virus (GTONNV)
Type of nucleic acid: ssDNA
Sequence: 5'GTCTGAAGTAGACGCAGGAGAACTGTATTAGCCTCTGGGTGCCGCACCGTAGTGCCCTATCTAACATCACAGTCACACCTGAGTAAGCGT3'
Sequence length: 90
GC content: 0.5222222222222223
Affinity: Kd: 39.21 nM
Pool type: 5′-GTCTGAAGTAGACGCAGGAG-N50-AGTCACACCTGAGTAAGCGT-3′
Pool random region: 50
Binding buffer/conditions: 5 g/L glucose, 1.0 g/L bovine serum albumin, 10 % FBS, 0.1 mg/mL yeast tRNA, 5 mM MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " These aptamers recognized GTONNV-infected cells with high specificity and affinity. The results also showed that these aptamers could inhibit GTONNV infection in vitro and in vivo. Moreover, the selected aptamers could be actively internalized into target cells, indicating their potential in targeted therapy and in the study of GTONNV pathogenesis."
Reference (2019, J Gen Virol ): Yu, Q., Liu, M., Wei, S., Wu, S., Xiao, H., Qin, X., Su, H., & Li, P. (2019). Characterization of ssDNA aptamers specifically directed against Trachinotus ovatus NNV (GTONNV)-infected cells with antiviral activities. The Journal of general virology, 100(3), 380–391. https://doi.org/10.1099/jgv.0.001226
Aptamer: Ylac1
Target: Lactoferrin
Type of nucleic acid: ssDNA
Sequence: 5'AGGCAGGACACCGTAACCGGTGCATCTATGGCTACTAGCTTTTCCTGCCT3'
Sequence length: 50
GC content: 0.54
Affinity: Kd: 2.2 ± 0.022 nM
Pool type: 5'-GACAGGCAGGACACCGTAAC-N40-CTGCTACCTCCCTCCTCTTC-3'
Pool random region: 40
Binding buffer/conditions:  1 ×PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·12H2O, 2 mM KH2PO4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We report a novel method for efficiently screening aptamers from a complex ssDNA library based on silver decahedral nanoparticles (AgNP) and fluorescence activated cell sorting (FACS). In this method, target protein (lactoferrin) and negative proteins (α-lactalbumin, β-lactoglobulin, bovine serum albumin, casein) were respectively immobilized on polystyrene microspheres (PS) to form PSLac, PSα-Lac, PSβ-Lac, PSBSA and PSCas. Six aptamers (Ylac1, Ylac4, Ylac5, Ylac6, Ylac8 and Ylac9) were obtained after five-round of selection. These aptamers showed good specificity towards lactoferrin in the presence of negative proteins. In a word, AgNP-FACS SELEX (AgFACS-SELEX) is a rapid, sensitive and highly efficient method for screening aptamers."
Reference (2019, Talanta ): Yu, F., Li, H., Sun, W., Zhao, Y., Xu, D., & He, F. (2019). Selection of aptamers against Lactoferrin based on silver enhanced and fluorescence-activated cell sorting. Talanta, 193, 110–117. https://doi.org/10.1016/j.talanta.2018.09.063
Aptamer: Ylac4
Target: Lactoferrin
Type of nucleic acid: ssDNA
Sequence: 5'GCAGGACACCGTAACGGGCGCACGCTCTGAATTTTGCATATGAAACAATTCTGTCCTGC3'
Sequence length: 59
GC content: 0.5084745762711864
Affinity: Kd: 4.0 ± 0.49 nM
Pool type: 5'-GACAGGCAGGACACCGTAAC-N40-CTGCTACCTCCCTCCTCTTC-3'
Pool random region: 40
Binding buffer/conditions:  1 ×PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·12H2O, 2 mM KH2PO4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We report a novel method for efficiently screening aptamers from a complex ssDNA library based on silver decahedral nanoparticles (AgNP) and fluorescence activated cell sorting (FACS). In this method, target protein (lactoferrin) and negative proteins (α-lactalbumin, β-lactoglobulin, bovine serum albumin, casein) were respectively immobilized on polystyrene microspheres (PS) to form PSLac, PSα-Lac, PSβ-Lac, PSBSA and PSCas. Six aptamers (Ylac1, Ylac4, Ylac5, Ylac6, Ylac8 and Ylac9) were obtained after five-round of selection. These aptamers showed good specificity towards lactoferrin in the presence of negative proteins. In a word, AgNP-FACS SELEX (AgFACS-SELEX) is a rapid, sensitive and highly efficient method for screening aptamers."
Reference (2019, Talanta ): Yu, F., Li, H., Sun, W., Zhao, Y., Xu, D., & He, F. (2019). Selection of aptamers against Lactoferrin based on silver enhanced and fluorescence-activated cell sorting. Talanta, 193, 110–117. https://doi.org/10.1016/j.talanta.2018.09.063
Aptamer: Ylac5
Target: Lactoferrin
Type of nucleic acid: ssDNA
Sequence: 5'AGGCAGGACACCGTAACGGTGCGGTCATATCCGGCTTTGCTTTTCCTGCCT3'
Sequence length: 51
GC content: 0.5686274509803921
Affinity: Kd: 4.7 ± 0.54 nM
Pool type: 5'-GACAGGCAGGACACCGTAAC-N40-CTGCTACCTCCCTCCTCTTC-3'
Pool random region: 40
Binding buffer/conditions:  1 ×PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·12H2O, 2 mM KH2PO4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We report a novel method for efficiently screening aptamers from a complex ssDNA library based on silver decahedral nanoparticles (AgNP) and fluorescence activated cell sorting (FACS). In this method, target protein (lactoferrin) and negative proteins (α-lactalbumin, β-lactoglobulin, bovine serum albumin, casein) were respectively immobilized on polystyrene microspheres (PS) to form PSLac, PSα-Lac, PSβ-Lac, PSBSA and PSCas. Six aptamers (Ylac1, Ylac4, Ylac5, Ylac6, Ylac8 and Ylac9) were obtained after five-round of selection. These aptamers showed good specificity towards lactoferrin in the presence of negative proteins. In a word, AgNP-FACS SELEX (AgFACS-SELEX) is a rapid, sensitive and highly efficient method for screening aptamers."
Reference (2019, Talanta ): Yu, F., Li, H., Sun, W., Zhao, Y., Xu, D., & He, F. (2019). Selection of aptamers against Lactoferrin based on silver enhanced and fluorescence-activated cell sorting. Talanta, 193, 110–117. https://doi.org/10.1016/j.talanta.2018.09.063
Aptamer: Ylac6
Target: Lactoferrin
Type of nucleic acid: ssDNA
Sequence: 5'GCAGGACACCGTAACGGGCGCACGCTCTGAATTTTTCATATGAAACAATTCTGTCCTGC3'
Sequence length: 59
GC content: 0.4915254237288136
Affinity: Kd: 1.9 ± 0.23 nM
Pool type: 5'-GACAGGCAGGACACCGTAAC-N40-CTGCTACCTCCCTCCTCTTC-3'
Pool random region: 40
Binding buffer/conditions:  1 ×PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·12H2O, 2 mM KH2PO4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We report a novel method for efficiently screening aptamers from a complex ssDNA library based on silver decahedral nanoparticles (AgNP) and fluorescence activated cell sorting (FACS). In this method, target protein (lactoferrin) and negative proteins (α-lactalbumin, β-lactoglobulin, bovine serum albumin, casein) were respectively immobilized on polystyrene microspheres (PS) to form PSLac, PSα-Lac, PSβ-Lac, PSBSA and PSCas. Six aptamers (Ylac1, Ylac4, Ylac5, Ylac6, Ylac8 and Ylac9) were obtained after five-round of selection. These aptamers showed good specificity towards lactoferrin in the presence of negative proteins. In a word, AgNP-FACS SELEX (AgFACS-SELEX) is a rapid, sensitive and highly efficient method for screening aptamers."
Reference (2019, Talanta ): Yu, F., Li, H., Sun, W., Zhao, Y., Xu, D., & He, F. (2019). Selection of aptamers against Lactoferrin based on silver enhanced and fluorescence-activated cell sorting. Talanta, 193, 110–117. https://doi.org/10.1016/j.talanta.2018.09.063
Aptamer: Ylac9
Target: Lactoferrin
Type of nucleic acid: ssDNA
Sequence: 5'CAGGCAGGACACCGTAACCTTTCAGGGTGGTGCCGTTTCGGGCTTTGTCTCTTCCTGCCTG3'
Sequence length: 61
GC content: 0.5901639344262295
Affinity: Kd: 2.6 ± 0.34 nM
Pool type: 5'-GACAGGCAGGACACCGTAAC-N40-CTGCTACCTCCCTCCTCTTC-3'
Pool random region: 40
Binding buffer/conditions:  1 ×PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·12H2O, 2 mM KH2PO4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We report a novel method for efficiently screening aptamers from a complex ssDNA library based on silver decahedral nanoparticles (AgNP) and fluorescence activated cell sorting (FACS). In this method, target protein (lactoferrin) and negative proteins (α-lactalbumin, β-lactoglobulin, bovine serum albumin, casein) were respectively immobilized on polystyrene microspheres (PS) to form PSLac, PSα-Lac, PSβ-Lac, PSBSA and PSCas. Six aptamers (Ylac1, Ylac4, Ylac5, Ylac6, Ylac8 and Ylac9) were obtained after five-round of selection. These aptamers showed good specificity towards lactoferrin in the presence of negative proteins. In a word, AgNP-FACS SELEX (AgFACS-SELEX) is a rapid, sensitive and highly efficient method for screening aptamers."
Reference (2019, Talanta ): Yu, F., Li, H., Sun, W., Zhao, Y., Xu, D., & He, F. (2019). Selection of aptamers against Lactoferrin based on silver enhanced and fluorescence-activated cell sorting. Talanta, 193, 110–117. https://doi.org/10.1016/j.talanta.2018.09.063
Aptamer: Tr-1
Target: Soluble Interleukin 2 Receptor α (CD25)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGGACGAUGCGGUCCUGUCGUCUGUUCGUCCCCAGACGACUCGCCCGA3'
Sequence length: 51
GC content: 0.6666666666666666
Affinity: Kd: 122.0 ± 5.23 nM
Pool type: 5'-GGGAGGACGAUGCGG-N20-CAGACGACUCGCCCGA-3'
Pool random region: 20
Binding buffer/conditions: HEPES-buffered saline, pH 7.5 with 2 mmol/L CaCl2) containing BSA (0.1 mg/mL) and tRNA (0.1 mg/mL)
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " serve as a high-throughput biomarker platform to quantify the fraction of receptors occupied by a ligand. In summary, this report described an assay platform, designated the LIRECAP assay, that is based on pairs of RNA aptamers that bind differentially based on the presence or absence of ligand. Such assays can be used to quantify the fraction of receptors occupied by ligand in a variety of biospecimens. Here, the IL2-CD25 complex as a biomarker for lymphoma was used in these proof-of-principle studies. However, a similar approach could be applied to a broad variety of molecular complexes and disease conditions."
Reference (2019, Cancer Immunol Res ): Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019). An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer immunology research, 7(9), 1511–1522. https://doi.org/10.1158/2326-6066.CIR-18-0821
Aptamer: Tr-6
Target: Soluble Interleukin 2 Receptor α (CD25)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGGACGAUGCGGCGUUUCCUCUGGUUCGUCCCCAGACGACUCGCCCGA3'
Sequence length: 51
GC content: 0.6666666666666666
Affinity: Kd: 96.9 ± 5.77 nM
Pool type: 5'-GGGAGGACGAUGCGG-N20-CAGACGACUCGCCCGA-3'
Pool random region: 20
Binding buffer/conditions: HEPES-buffered saline, pH 7.5 with 2 mmol/L CaCl2) containing BSA (0.1 mg/mL) and tRNA (0.1 mg/mL)
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " serve as a high-throughput biomarker platform to quantify the fraction of receptors occupied by a ligand. In summary, this report described an assay platform, designated the LIRECAP assay, that is based on pairs of RNA aptamers that bind differentially based on the presence or absence of ligand. Such assays can be used to quantify the fraction of receptors occupied by ligand in a variety of biospecimens. Here, the IL2-CD25 complex as a biomarker for lymphoma was used in these proof-of-principle studies. However, a similar approach could be applied to a broad variety of molecular complexes and disease conditions."
Reference (2019, Cancer Immunol Res ): Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019). An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer immunology research, 7(9), 1511–1522. https://doi.org/10.1158/2326-6066.CIR-18-0821
Aptamer: Tr-7
Target: Soluble Interleukin 2 Receptor α (CD25)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGGACGAUGCGGUGAGUCGUUCCCUUCGUCCCCAGACGACUCGCCCGA3'
Sequence length: 51
GC content: 0.6666666666666666
Affinity: Kd: 68.2 ± 2.73 nM
Pool type: 5'-GGGAGGACGAUGCGG-N20-CAGACGACUCGCCCGA-3'
Pool random region: 20
Binding buffer/conditions: HEPES-buffered saline, pH 7.5 with 2 mmol/L CaCl2) containing BSA (0.1 mg/mL) and tRNA (0.1 mg/mL)
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " serve as a high-throughput biomarker platform to quantify the fraction of receptors occupied by a ligand. In summary, this report described an assay platform, designated the LIRECAP assay, that is based on pairs of RNA aptamers that bind differentially based on the presence or absence of ligand. Such assays can be used to quantify the fraction of receptors occupied by ligand in a variety of biospecimens. Here, the IL2-CD25 complex as a biomarker for lymphoma was used in these proof-of-principle studies. However, a similar approach could be applied to a broad variety of molecular complexes and disease conditions."
Reference (2019, Cancer Immunol Res ): Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019). An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer immunology research, 7(9), 1511–1522. https://doi.org/10.1158/2326-6066.CIR-18-0821